

Bulletin Number: MSA 16-06

Distribution: All Providers

Issued: March 1, 2016

Subject: Transition to Managed Care Common Formulary

Effective: April 1, 2016

Programs Affected: Medicaid, Healthy Michigan Plan, Children's Special Health Care Services (CSHCS)

This policy outlines the transition plan for current members who are enrolled in a Medicaid Health Plan (MHP) and have been taking a drug that is not on the Managed Care Common Formulary. Refer to bulletin MSA 15-55 for an overview of the Common Formulary policy. With the exception of drug therapies that have been grandfathered, it is expected that all members' drug therapies will be transitioned to the Common Formulary by September 30, 2016. See below for drug classes that have been grandfathered.

If a member enrolls in a MHP on or after April 1, 2016 and has been taking a drug that is not on the Common Formulary, he/she may need to obtain a prior authorization (PA) to continue the drug therapy.

Grandfathered Drug Classes

The transition plan requires the MHPs to allow members to continue taking drugs in select drug classes without any PA until April 1, 2017. After April 1, 2017, if the Common Formulary indicates the drug requires PA, the MHPs may require PA for the member to continue the drug therapy. These select drug classes will be referred to as "grandfathered drug classes" and include:

- Antineoplastics
- Immunosuppressants
- Disease-Modifying Medications for Multiple Sclerosis

Members Taking Maintenance Drugs

If a member is taking a maintenance drug that is not on the Common Formulary without PA, the MHP must send at least one notice to the member and at least one notice to the member's prescriber informing them of the member's options to obtain a PA to continue on the drug therapy or to switch to a therapeutic alternative drug that is on the Common Formulary that does not require PA.

For the purposes of this policy, a maintenance drug is defined as a drug where the member has received a 60-day supply of the drug in the previous 90 days. The MHP must allow the member to continue taking a maintenance drug for at least 90 days following the date of the notice to the member.

If a notice dated on or before August 31, 2016 is not sent to the member, the MHP must allow the member to continue taking the drug without PA or step therapy requirements until April 1, 2017. After that date the health plan may require the member to obtain a PA to continue taking the drug.

Members in the CSHCS Program

If a member in the CSHCS program is taking a drug that is not on the Common Formulary without PA, the MHP must send at least one notice to the member and at least one notice to the member's prescriber informing them of the options to obtain a PA to continue taking the drug, or to switch to a therapeutic alternative drug that is on the Common Formulary without PA. The MHP must allow the member to continue taking the drug for at least 90 days following the date of the notice to the member.

If a notice dated on or before August 31, 2016 is not sent to the member, the MHP must allow the member to continue taking the drug without PA or step therapy requirements until April 1, 2017. After that date the health plan may require the member to obtain a PA to continue taking the drug.

Manual Maintenance

Retain this bulletin until the information is incorporated into the Michigan Medicaid Provider Manual.

Questions

Any questions regarding this bulletin should be directed to Provider Inquiry, Department of Health and Human Services, P.O. Box 30731, Lansing, Michigan 48909-8231, or e-mail at ProviderSupport@michigan.gov. When you submit an e-mail be sure to include your name, affiliation, and phone number so you may be contacted if necessary. Providers may phone toll-free 1-800-292-2550.

Approved



Chris Priest, Director
Medical Services Administration